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Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest of all solid tumours and more 
effective therapy is urgently needed. The stroma is thought to play a critical role in tumour 
development and metastasis, and high stromal expression of the matricellular protein SPARC has 
been robustly associated with poor patient prognosis.  However, the precise role of SPARC has been 
highly controversial, with multiple studies demonstrating tumour-suppressor properties of this 
protein in vitro.  This conflicting data has been a barrier to the development of new therapeutic 
approaches targeting SPARC, despite current interest in stromal-therapy.  
We show conclusively that SPARC acts directly on cancer cells to promote pancreatic cancer cell 
proliferation.  This contradicts previous in vitro studies, but is consistent with the observed clinical 
association between SPARC expression and poor patient prognosis. However, depletion of 
fibronectin switches the activity of SPARC from promoting cancer cell proliferation to growth 
inhibition and induction of apoptosis. Thus, targeting the interaction between SPARC and fibronectin 
could be used to turn the highly expressed tumour protein SPARC against the tumour to induce 
tumour cytotoxicity, and is a novel target for PDAC therapy. 
 




Pancreatic ductal adenocarcinoma (PDAC) is a devastating disease, with one of the lowest survival 
rates of all cancers [1].  New therapeutic targets are urgently needed. One striking pathological 
feature of PDAC is the extent of the tumour stroma. The complex interaction between cancer cells, 
stromal cells and the extracellular matrix is thought to contribute to both tumour development and 
chemotherapy resistance. Activated pancreatic stellate cells are important drivers of the stromal 
response, causing an enhanced secretion of growth factors, cytokines and matrix proteins that 
supports cancer cell proliferation and metastasis [2].  SPARC is a stroma-derived protein that plays a 
critical role in this desmoplastic response [3].  High SPARC expression is strongly associated with 
poor patient prognosis in resectable and locally advanced pancreatic cancer [4–8]. Furthermore, it is 
clear that while SPARC is normally expressed at low levels in adult tissues, pancreatic tumours 
commonly express high levels of SPARC [9,10].  In line with this, serum SPARC level is being explored 
as a screening marker for pancreatic cancer [11].   
The precise role of SPARC in tumour development and progression remains unclear.  SPARC is a 
matricellular protein, capable of interacting with extracellular components such as matrix proteins 
and growth factors, as well as cell surface receptors such as integrins and growth factor receptors 
[12]. It is involved in varied cellular processes including proliferation, apoptosis, adhesion and 
migration, as well as matrix remodelling and angiogenesis [13]. However, despite the strong clinical 
association between SPARC over-expression and pancreatic cancer, published in vitro experiments to 
date conversely suggest that SPARC inhibits pancreatic cell proliferation and promotes apoptosis 
[9,14,15]. 
Our goal was to investigate this apparent contradiction using a range of in vitro models to examine 
the effect of SPARC in both stromal and cancer compartments.  In doing so, we have discovered a 
novel therapeutic target for pancreatic cancer that allows us to ‘switch’ the highly tumour-expressed 
SPARC protein from promoting cancer cell growth to inducing pancreatic cancer cell apoptosis. This 
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may in the future allow us to turn the stroma against the cancer to more effectively treat this 
devastating disease. 
 
2. Materials and Methods 
2.1 Cell Culture 
PS-1 cells were originally isolated from a donated human pancreas and immortalised as described 
previously [16]. PDAC cell lines AsPC-1, Panc-1, Hpaf and Capan-1 were kindly provided by Dr 
Charlotte Edling, formerly of the Blizard Institute, Barts and the London Queen Mary University of 
London. All cell lines were maintained in RPMI-1640 media supplemented with 10% FBS, 2mM L-
glutamine, 100U/ml penicillin and 100µg/ml streptomycin purchased from Fisher Scientific, UK. Cells 
were incubated at 37°C in humidified air with 5% CO2. All cell lines were sub-cultured every 3-4 days 
and used within 10 passages.  
Additional proteins used for cell culture were as follows: rhSPARC (#941-SP-050, R&D Systems; His-
tagged), active TGFE (Abcam #ab50036), and fibronectin (#10042682, Fisher Scientific). Cell culture 
medium containing albumin was produced by substituting FBS with 2.5% BSA (Sigma-Aldrich, UK) 
which is equivalent to the amount of albumin in 10% FBS.  
Cell culture medium containing FBS depleted of fibronectin (FN) was produced using Gelatin-
Sepharose 4B (#17-0956-01, GE Healthcare), which binds to fibronectin with high specificity, adapted 
from the protocol described by Liu and Collodi [17]. Gelatin Sepharose 4B is supplied pre-swollen in 
20% ethanol. The EtOH layer was removed by centrifugation and discarded. The beads were washed 
with PBS and 8ml was added to 50ml of FBS and the solutions were mixed on a lab tube roller mixer 
at 4˚C for 48hrs. Post-mixing, the FBS solution was centrifuged and the layer of fibronectin bound 
gelatin-sepharose 4B was discarded. This step was repeated once more and the resulting FBS was 
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filter sterilised (0.2µm). RPMI-1640 medium was supplemented with 10% FBS depleted of FN, 2mM 
L-glutamine, 100U/ml penicillin and 100µg/ml streptomycin. 
2.2 Cell Proliferation Assay  
AsPC-1, Capan-1, Hpaf-2, Panc-1 and PS-1 cells were plated at a density of 2x103 or 4x103 cells/well in 
a 96 well plate and treated with 0.5% FBS medium overnight. Cells were then treated +/- 10µg/ml 
rhSPARC, or with conditioned medium from siRNA transfected PS-1 cells, in the FBS conditions 
indicated. BrdU incorporation (Roche Applied Science) was measured for the last 24 hours of a 72 
hour culture according to the manufacturer’s instructions. Absorbance was read at 370nm on an 
Epoch Microplate Spectrophotometer (BioTek). In Figure 3A, 4x104 PS-1 cells were seeded in a 24 
well plate and transfected with SPARC or control siRNA. The cells were counted using a 
haemocytometer after a 48hr transfection period.  
2.3 Transwell Model 
AsPC-1 cells were plated at a density of 1.5x105 cells/well in a 6 well insert companion plate (BD 
Biosciences) in complete medium. PS-1 cells previously transfected with either SPARC or control 
siRNA were introduced to the well using a 1µm porous insert (BD Biosciences). AsPC-1 cell number 
was counted using a haemocytometer for 5 consecutive days after the co-culture, or at day 6 with 
representative images captured using an IncuCyte Zoom Live cell imaging system.  
2.4 siRNA Transfection  
Transfection of PS-1 cells was carried out as described previously [18]. Briefly, transfection 
complexes were formed by mixing control- or SPARC-siRNA (Dharmacon, GEHealthcare) in HiPerFect 
transfection medium (Qiagen). During this period, PS-1 cells were cultured in a 24 well plate and 
subsequently treated with the transfection reagents to give a final siRNA concentration of 80nM, 
unless otherwise stated. The Dharmacon siRNA used were as follows: control non-targeting siRNA 
#J-001810-01; SPARC-targeting siRNA #J-003710-10 was used in all experiments except those shown 
in Figure 1E and Figure 5B, where an alternative SPARC-targeting siRNA #J-003710-09 was used. PS-1 
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cells were transfected for 48hrs and SPARC knockdown was confirmed by western blot (see Figure 1 
for validation of siRNA knockdown).  
2.5 PS-1 Cell Activation Assay/ Immunocytochemistry 
All-trans retinoic acid (ATRA) has previously been shown to inactivate PS-1 cells [19]. ATRA (Sigma-
Aldrich) was reconstituted in ethanol and stock ATRA solution was protected from light, stored at -
80˚C and used within 2 weeks of reconstitution. Sterile #1.5 coverslips were placed in 6 well plates. 
PS-1 cells were seeded at density of 1x105 cells/well in complete medium containing 1µM ATRA or 
vehicle control (Sigma-Aldrich). The plate was incubated for 7 days and the culture medium was 
replenished with fresh medium at day 3. At day 7, the cells were fixed with 4% PFA, blocked with 
10% normal horse serum, incubated with an anti-GFAP antibody (Sigma-Aldrich) for 2hrs followed by 
a 1hr incubation with AlexaFluor488 secondary antibody. Slides were imaged using a 20x objective 
on a FLoid imaging station (Life Technologies). Cell lysates were also prepared at day 7 for western 
blot. 
PS-1 cells transfected with either SPARC or control siRNA were plated on coverslips in a 6 well plate 
at a density of 1x105 cells/ml in low serum (0.5% FBS) or complete medium (10% FBS) for 72hrs. Cells 
were fixed with 10% NBF, permeabilised with 0.1% Triton-X, blocked with 10% NHS, incubated with 
an anti-vimentin primary antibody (Dako) for 2hrs and an Alexafluor488 secondary antibody (Life 
Technologies) for 1hr. Slides were imaged at 10x lens on a EVOS microscope (AMG). See 
Supplementary Table 1 for antibody details. 
2.6 Collagen I immunocytochemistry 
SPARC/control siRNA transfected PS-1 cells were re-plated into a 6-well plate containing sterilized 
coverslips and cultured for 72hrs. Post culture, the cells were washed in PBS and fixed with 4% PFA 
for 10 min at RT, washed again and blocked in 10% normal horse serum for 30 min at RT. The cells 
were incubated overnight at 4˚C with anti-collagen I antibody (#ab19811, Abcam), then washed and 
incubated with an Alexafluor 488 secondary (#A-11055, Invitrogen) for 1hr at RT. The cells were then 
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incubated with DAPI (1:1000 dilution, #D3571, Invitrogen) for 5min at RT. The cells were washed and 
mounted onto slides and imaged with a Zeiss LSM confocal microscope.  
2.7 Western Blot 
Cells lysates were made with RIPA lysis buffer containing Halt protease inhibitor cocktail (Thermo 
Scientific). Lysate supernatant was collected after centrifugation. Protein was quantified using a BCA 
assay (Bio-Rad) before loading according to manufacturer’s instructions, and an anti-E actin antibody 
was used as a loading control. The lanes have been re-ordered for clarity in some blots. 
For glycosylase experiments, PNGase F was incubated with the lysates for 1hr at 37˚C post 
denaturation at 100˚C according to manufacturer’s protocol (New England Biosciences).                                                                               
After the addition of 5X sample buffer, proteins were resolved using handmade 12% SDS-PAGE gels, 
transferred onto a nitrocellulose membrane using semi-dry transfer, and blocked with 5% semi-
skimmed milk in TTBS. The membranes were incubated overnight at 4˚C with relevant primary 
antibodies against SPARC, TGF-β or vimentin and β-actin. Goat anti-rabbit and anti-mouse IgG 
secondary antibodies conjugated to IR700 and IR800 infra-red dyes were used for detection and the 
Odyssey CLx Infrared Imaging System (Li-Cor) was used for visualisation. Band molecular weight and 
intensity quantification was measured using Li-Cor Image Studio Lit version 4.0. See Supplementary 
Table 1 for antibody details.   
The blots for collagen and DSMA were performed similarly but with the following differences.  10µg 
of protein were loaded per lane on a 4–20% Mini-PROTEAN TGX Precast Protein Gels (#4561093, 
Bio-Rad). A Tansblot Turbo Transfer System (Bio-Rad) was used to transfer proteins onto a 0.2µm 
nitrocellulose membrane. A Trans-Blot Turbo RTA Mini Nitrocellulose Transfer Kit (#1704270, Bio-
Rad) was used according to manufacturer’s instruction. Membranes were incubated with primary 




For SPARC secretion, an RnD Systems Human SPARC Quantikine ELISA Kit (#DSP00) was used.  
Conditioned medium from SPARC/control siRNA transfected PS-1 cells (in 0.5% FBS) was collected 
and diluted 8-fold in Calibrator Diluent RD6-59. To quantify fibronectin, a bovine Fibronectin ELISA 
Kit (Sigma #RAB1011-1KT) was used, which also recognises human fibronectin. Samples of FBS and 
FBS depleted of FN were diluted 500-fold in Assay/Sample Diluent buffer, or for PS-1-conditioned 
media samples were diluted 50-fold. Standards were prepared and the protocol was carried out 
according to the manufacturer’s instructions for both kits. Absorbance was read at 450nm using a 
FLUORstar microplate reader (BMG Labtech).   
2.9 Caspase-3/7 apoptosis assay 
Cancer cells were seeded at a density of 4,000 cells/well in a 96 well plate in low serum medium 
overnight to synchronize. The cells were treated with 10µg/ml rhSPARC, or left untreated, in 
complete or low serum medium supplemented with 5µm unlabelled caspase -3/-7 substrate (DEVD) 
that releases a green DNA binding fluorescent label upon caspase cleavage (Essen Bioscience). 
Apoptotic cells therefore fluoresce.  An IncuCyte Zoom Live Cell Imaging System was used to capture 
phase contrast and green fluorescence images over 72hrs. The IncuCyte Zoom 2015A software was 
used to calculate the stained apoptotic cell area in the images.  
2.10 Annexin V apoptosis assay 
AsPC-1 cells were seeded at a density of 50,000 cells/well in a 12-well plate overnight in low serum 
(0.5% FBS) medium to synchronize the cells. The cells were subsequently treated with or without 
10µg/ml rhSPARC in complete or FN depleted medium and cultured for 72hrs. Post culture, the cells 
were resuspended in medium and 10µl was removed for cell counting using a hemocytometer. The 
remaining cell suspension was washed with PBS and resuspended in a 100µl of 1X Annexin binding 
buffer (#556454, BD Bioscience) diluted in cold PBS. Samples were incubated with 5µl FITC Annexin 
V (#560931, BD Bioscience) and 5µl 7AAD (#559925, BD Bioscience) and incubated for 15min at RT in 
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the dark. A further 400µl of 1X binding buffer was added to each sample before being analysed 
immediately using a flow cytometer (BD Bioscience). 
2.11  Statistics 
Statistical significance was measured using unpaired two-tailed Student’s T-test unless indicated as a 
two-way ANOVA.  A p value of ≤0.05 was considered statistically significant. Error bars represent 
standard error of the mean (SEM). 
 
3. Results  
3.1 Stromal cell secreted SPARC promotes pancreatic cancer cell growth. 
SPARC is primarily expressed by stromal cells in both PDAC tumours and cell lines [5,14,15]. 
Consistent with this, SPARC was detectable at high levels in pancreatic stellate (PS-1) cells in our 
hands by western blot [20], and was undetectable in pancreatic cancer cells (Figure 1A).  In order to 
examine the effect of stromal-derived SPARC on pancreatic cancer cell proliferation, we treated PS-1 
cells with either control- or SPARC-siRNA, typically achieving ~85% knockdown (Figure 1B-E).  SPARC 
siRNA treatment also reduced SPARC secretion by ~75%, as determined by ELISA (Figure 1F). 
Conditioned media from these PS-1 cells was then used to culture pancreatic cancer cells.  As shown 
in Figure 2A, the proliferation of cancer cells cultured in SPARC-knockdown PS-1 cell medium was 
significantly reduced compared to cancer cells cultured in medium from control PS-1 cells.  
Pancreatic cancer proliferation was also found to be reduced by around 50% in the absence of PS-1-
derived SPARC in experiments using a transwell model, as determined both by manual counting and 
quantitative imaging (Figure 2B&C).  Together, these experiments show that PS-1-derived SPARC 
promotes pancreatic cancer proliferation, in direct contrast to previously reported studies [14,15], 
but consistent with clinical observations linking high SPARC expression with poor patient prognosis 
[4–8]. 
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3.2 SPARC protein expression is upregulated in activated pancreatic stellate cells but does not exhibit 
cell autonomous action. 
To try to identify the reason behind the difference between our results and those previously 
reported, we hypothesized that PS-1-derived SPARC may act in a cell autonomous manner to 
promote PS-1 cell activation and the production of secreted factors, thereby indirectly promoting 
pancreatic cancer cell proliferation. We therefore conducted a series of experiments to examine 
whether SPARC siRNA knockdown affects the activation of PS-1 cells. Activated PS-1 cells are known 
to have increased proliferation and increased expression of the cytoskeletal protein vimentin 
compared to quiescent cells [19]. However, there was no evidence of any difference in PS-1 
proliferation either directly following SPARC siRNA knockdown, as determined by manual cell 
counting (Figure 3A) and quantitative Image J analysis (Figure 3G), or following re-plating and culture 
in conditioned media, as determined by BrdU assay (Figure 3B). Similarly, treatment with 
recombinant SPARC did not affect PS-1 cell proliferation (Figure 3C). Western blot and 
immunocytochemistry staining for vimentin in PS-1 cells following transfection with control- or 
SPARC-siRNA showed no change in vimentin expression (Figure 3D-F). Expression of the important 
cancer growth factor TGF-β also remained unchanged in SPARC-siRNA transfected PS-1 cells over 3 
days (Figure 3H&I). Furthermore, no significant change in the expression of collagen I was observed 
by quantitative confocal microscopy (Suppl. Figure 2F-H), although a slight increase in collagen I was 
detected in SPARC knockdown cells by Western blot (Suppl. Figure 2I), consistent with previous 
reports [21]. No difference in fibronectin secretion was observed, as determined by ELISA (Suppl. 
Figure 3B). Similarly, no clear difference in expression of the myofibroblast activation marker D-SMA, 
which has been associated with a tumour-suppressive subset of myofibroblasts [22], was observed 
(Suppl. Figure 2J). Taken together, this data shows that no difference in PS-1 activation was detected 
following SPARC siRNA knockdown. We were therefore unable to find any evidence of SPARC playing 
a cell autonomous role, suggesting instead that SPARC secreted by PS-1 cells acts directly on 
pancreatic cancer cells to enhance their proliferation.  
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Interestingly, however, SPARC expression was significantly higher in activated PS-1 cells compared to 
quiescent cells (Suppl. Figure 1).  We used all-trans retinoic acid (ATRA) to induce quiescence in PS-1 
cells [19], and observed the expected increase in expression of the quiescence marker glial fibrillary 
acidic protein (GFAP), as well as a decrease in cell density, reflective of decreased proliferation 
following ATRA treatment. The increased expression of SPARC in activated pancreatic stellate cells is 
consistent with the clinically observed enhanced production of SPARC by aberrantly activated 
stromal cells in PDAC.  
3.3 Purified SPARC recapitulates the effect of PS-1-derived SPARC in promoting pancreatic cancer cell 
growth. 
In the absence of evidence that SPARC affects PS-1 activation in a cell autonomous manner, we 
therefore focused on mechanisms in which SPARC acts directly on pancreatic cancer cells. We 
hypothesized that purified SPARC, as used in previous studies [9,14,15], may be distinct to stromal-
derived SPARC.  SPARC is known to be glycosylated [23] and tissue-specific glycosylation patterns, or 
indeed tissue-specific isoform expression, could influence SPARC function. However, there was no 
evidence of any difference in molecular weight between rhSPARC and PS-1-derived SPARC over and 
above the expected slightly higher molecular weight of rhSPARC due to the presence of the His-tag 
(Figure 4A&B).  Following removal of N-linked glycosylation by PNGase treatment, a mean shift in 
molecular weight of 3.1 kDa and 2.6 kDa was seen in rhSPARC and PS-1-derived SPARC, respectively, 
confirming glycosylation of both forms of SPARC, and potentially slightly increased glycosylation of 
the recombinant form compared to stromal SPARC.  However, surprisingly, treatment with rhSPARC 
at a concentration similar to published studies [9,14,15] increased the proliferation of pancreatic 
cancer cells in our hands (Figure 4C), entirely consistent with the effect of stromal SPARC (Figure 2).  
Therefore potential differences in post-translational modification or cell-type specific isoform 
expression do not explain the contradiction between our observations and that in the literature of 
the effect of SPARC on pancreatic cancer cell proliferation.  
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3.4 Fibronectin switches SPARC activity from promoting pancreatic cancer cell growth to inducing 
cancer cell apoptosis. 
Many of the published in vitro studies of SPARC were conducted under low or unspecified serum 
conditions [9,14,15], while we had used standard 10% serum in our assays.  We therefore tested 
whether performing our experiments in low serum conditions affected the outcome. Culture of 
pancreatic cancer cells in low serum (0.5% FBS) conditioned medium from PS-1 cells transfected with 
control- or SPARC-siRNA showed, strikingly, that SPARC inhibits pancreatic cancer cell proliferation 
under low serum conditions (Figure 5A). This is in direct contrast to our previous observations in 
complete medium (Figure 2 and Figure 4C).  The results were confirmed using a second siRNA 
targeting a distinct SPARC sequence, clearly demonstrating that the contrasting effects of SPARC are 
determined by serum conditions (Figure 5B). Experiments to test for cell autonomous functions of 
SPARC in PS-1 cells under low serum conditions showed that neither rhSPARC nor PS-1 derived 
SPARC has any effect on PS-1 cell proliferation or TGF-β expression (Supplementary Figure 2), 
consistent with observations in complete medium (Figure 3), suggesting that SPARC also acts directly 
on pancreatic cancer cells under low serum conditions. 
We then performed a systematic in silico analysis of proteins for which there is evidence for 
interaction with SPARC and that are present in serum and may therefore be responsible for the 
switch between pro- and anti-proliferative SPARC function under different serum conditions 
(Supplementary Table 2). Although not exhaustive, the analysis revealed that of the 24 proteins for 
which there is evidence of interaction with SPARC in either the STRING or Gene/NCBI databases, 10 
of these are typically present in serum, including albumin, TGF-β and fibronectin.  
SPARC was originally identified as albumin-binding protein and albumin constitutes approximately 
half the total protein in plasma [24–26].  We therefore tested whether adding albumin into low 
serum cultures was able to ‘switch’ the effect of SPARC on pancreatic cancer cell proliferation. AsPC-
1 cells were cultured with medium supplemented with 10% FBS, 0% FBS or 0.25% BSA (equivalent to 
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the BSA found in FBS) in the presence or absence of rhSPARC.  As shown in Figure 5C, rhSPARC 
promoted AsPC-1 proliferation in complete medium and inhibited growth in serum free medium, as 
expected. However, SPARC also inhibited cell growth in the presence of BSA added to serum-free 
medium, suggesting that albumin does not affect the ‘switch’ in SPARC function caused by serum 
conditions. 
 SPARC has been shown to regulate signalling downstream of TGF-β, which is an important tumour 
growth factor, and it has been shown experimentally that SPARC can interact with the TGF-β/type II 
receptor complex [27,28]. To determine the effect of TGF-β on SPARC function, AsPC-1 cells in low 
serum medium (0.5% FBS) were treated with 10µg/ml rhSPARC, 140 ng/ml rhTGF-β, or both rhSPARC 
and TGF-β. As expected, SPARC treatment alone inhibited AsPC-1 proliferation, while TGF-β 
treatment alone had no significant effect (Figure 5D).  However, TGF-β actually enhanced SPARC’s 
ability to inhibit pancreatic cancer cell proliferation under low serum conditions compared to 
treatment with SPARC alone. Therefore, since TGF-β did not reverse SPARC-induced growth 
inhibition under low serum conditions, TGF-β was excluded as the serum factor that regulates SPARC 
function.  
Fibronectin is also part of the SPARC interaction network (Suppl. Table 2), and is overexpressed in 
multiple tumours, including PDAC, as part of the desmoplastic reaction [29].  While fibronectin can 
be secreted locally by cells within tissues (cFN) it is also an abundant soluble plasma protein (pFN) 
[30]. Fibronectin can be depleted from serum using the well-established method of gelatin-
sepharose columns [31,32], and effective fibronectin depletion was achieved in our hands using this 
approach as determined by ELISA quantification of fibronectin before and after depletion (Suppl. 
Figure 3A). We therefore tested whether depletion of pFN is able to ‘switch’ the SPARC effect. 
Consistent with previous experiments, SPARC promoted growth of AsPC-1 cells in 10% FBS and 
inhibited proliferation in low serum medium. However, strikingly, when AsPC-1 cells were treated 
with rhSPARC in complete medium depleted of fibronectin, the proliferative effect of SPARC 
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observed in 10% FBS medium was lost (Figure 5E).  Instead, SPARC inhibited proliferation, mimicking 
the SPARC response in 0.5% FBS medium. This suggests that the presence of pFN in serum is 
responsible for ‘switching’ the effect of SPARC, such that in the presence of pFN SPARC promotes 
cell growth, while in conditions of low pFN SPARC inhibits cell growth.   
While fibronectin depletion using gelatin-sepharose beads is highly specific, a small number of other 
gelatin-binding serum proteins can also be depleted using this technique, specifically MMP-2 and 
MMP-9 [33], as well as glycosaminoglycans such as heparin [34,35].  We therefore purchased 
purified bovine fibronectin in order to add fibronectin to low serum cultures to test whether the 
addition of purified fibronectin mimics the presence of 10% FBS and ‘switches’ the SPARC response.  
Additional of either 500Pg/ml or 1 mg/ml fibronectin was sufficient to prevent the inhibition of cell 
proliferation induced by SPARC under low serum conditions (Figure 5F&G). Interestingly, SPARC did 
not cause increased proliferation when fibronectin was added, potentially due to the removal of 
heparin sulphate proteoglycans, which are known to be important for fibronectin function, during 
fibronectin purification. In summary, this data confirms that the presence of fibronectin controls 
SPARC activity. 
In order to test whether SPARC is able to actively induce cytotoxicity under low serum/low 
fibronectin conditions, we measured activity of caspase-3/7 following SPARC treatment under both 
low and standard serum conditions.  As shown in Figure 6A-C, in low serum conditions SPARC 
induces Caspase-3/7-activity, while in the presence of 10% serum SPARC inhibits Caspase-3/7 
activity.  Furthermore, treatment with SPARC in fibronectin-depleted 10% serum reduced cell 
number and increased apoptosis by ~50%, as shown by increased binding of Annexin-V (Figure 6D-F).  
Together, these data strongly suggest that inhibiting the interaction between SPARC and fibronectin 
would not only prevent SPARC from enhancing tumour growth, but would turn this highly expressed 
tumour stroma protein against the cancer cells to induce pancreatic cancer cell cytotoxicity.  
4. Discussion 
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Conflicting evidence for the pro-/anti-proliferative effects of SPARC in different contexts has been a 
barrier to the development of therapeutic strategies relating to SPARC, despite clinical evidence 
demonstrating the association between high stromal SPARC expression and poor patient outcome in 
multiple tumour types, including pancreatic cancer [4,36]. In vivo experiments have provided useful 
insights, but since studies to date have used a systemic SPARC knockout approach, rather than cell-
type specific, and since the lack of SPARC during development results in profound matrix 
abnormalities that are unlikely to reflect clinical pancreatic cancer, where SPARC is locally 
upregulated, the results overall have been challenging to interpret [37–43]. The interpretation of in 
vitro studies has been confounded by the wide array of different experimental scenarios, for 
example, knockdown/overexpression of endogenous SPARC in cancer cells versus modulation of 
SPARC in stromal cells or treatment of cancer cells with exogenous SPARC.  There is evidence that 
SPARC may function intracellularly in cancer cells [44], and it has been shown that cancer cells 
expressing SPARC secrete very little or no SPARC [14,15]. Therefore, modulation of SPARC expression 
endogenously within cancer cells is likely to have distinct effects to those of extracellular SPARC.  
Further adding to this complexity, protocols involving an array of different serum and stress 
conditions are also employed.  One conclusion that can be drawn from the confusing diversity of in 
vitro findings is that ‘context’ is important and influences the effect that SPARC has on cellular 
function. However, to date, no specific molecular basis for the hypothesized contextual factors that 
regulate SPARC function has been found.  On re-examining the literature, a number of early studies 
in other models also found indications that serum and matrix conditions can regulate SPARC 
function [45,46].  However, our data show specifically for the first time that the presence of plasma 
fibronectin determines the specific effect of SPARC on pancreatic cancer cell proliferation, 
supporting the idea that precise extracellular matrix composition is the ‘context’ that determines 
SPARC function, potentially via modulation of integrin signalling [40,47] SPARC can enhance 
fibronectin matrix deposition via an integrin-linked kinase (ILK)-dependent mechanism [48,49], and 
in the absence of SPARC, fibronectin-induced actin filament rearrangement is inhibited [48]. It will 
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therefore be important in future studies to establish whether SPARC regulation of fibronectin is 
relevant to the ‘switch’ in SPARC function that we have observed in the absence of fibronectin. 
The data shown here creates the exciting possibility that targeting interactions between specific 
matrix/matricellular proteins can be used to “fine-tune” the stroma, and represents a novel 
therapeutic approach for the treatment of solid tumours, particularly where there is a strong 
stromal component.  Both SPARC and fibronectin are overexpressed in the PDAC tumour stroma, 
and targeting the interaction between SPARC and fibronectin could potentially turn the highly 
tumour expressed protein SPARC against the tumour, such that instead of promoting tumour growth 
it instead induces tumour cytotoxicity.  The extracellular nature of this interaction makes it an 
attractive therapeutic target, with the additional potential advantage that intracellular SPARC 
functions would be left intact. There is clinical heterogeneity in terms of SPARC expression, and any 
future therapeutics targeting the SPARC-fibronectin interaction would likely benefit the ~2/3 of 
PDAC patients in which SPARC expression is upregulated in the stromal compartment [4]. 
In conclusion, we have shown that fibronectin acts as a molecular switch, controlling whether SPARC 
promotes pancreatic cancer cell proliferation or induces cancer cell cytotoxicity.  It will be important 
to determine whether blocking this interaction, perhaps using either existing or novel antibodies, 
can be used therapeutically to turn the stroma against the tumour to more effectively treat 
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Figure legends. 
Figure 1: Validation of SPARC knockdown (KD) in stromal PS-1 cells. (A) Western blot 
representative of 3 independent experiments showing SPARC expression in pancreatic 
cancer and stromal (PS-1) cells.  (B) PS-1 cells were treated with the indicated concentration 
of control- or SPARC (#J-003710-10)-siRNA, and western blot of SPARC expression (42kDa) is 
shown (n=1). (C) Graph shows percentage SPARC KD in transfection experiments in this study 
(80nM siRNA); dotted line shows mean KD. (D) Representative western blot shows SPARC KD 
using 80nM #J-003710-10 siRNA. (E) Western blot showing SPARC knockdown using an 
alternative SPARC siRNA (#J-003710-09). (F) SPARC secretion in conditioned media from PS-1 
cells treated with control- or SPARC siRNA, as determined by ELISA assay.  Graph shows 
mean SPARC (ng/ml) +/- SEM (n=3). 
 
Figure 2: Stroma-derived SPARC promotes pancreatic cancer cell proliferation in vitro. (A) 
pancreatic cancer cells were treated with conditioned medium from control- or SPARC-siRNA 
transfected PS-1 cells (10% FBS). Cell proliferation was measured by BrdU assay for the last 24hrs of 
72hr culture. Graph shows relative absorbance ±SEM (n=24-60 from 3-4 independent experiments). 
(B&C) AsPC-1 cells were co-cultured with PS-1 cells previously transfected with either control- or 
SPARC-siRNA (10%FBS) in a transwell model using a 1µm porous insert, and cancer cell density was 
determined by haemocytometre counting. (B) Graph shows mean AsPC-1 cell density over 5 
consecutive days ± SEM (n=4 from 4 independent experiments). (C) Graph shows mean relative 
AsPC-1 cell density at day 6 (n=9 from 3 independent experiments), and representative images are 
also shown.  
Figure 3: No evidence for autocrine effect of SPARC on pancreatic stellate cells. (A) graph shows 
mean relative PS-1 cell density ±SEM at 48 hours following siRNA transfection in a 24 well plate as 
determined by haemocytometer cell counting (n=18 from 4 independent experiments). (B) Following 
control-/SPARC-siRNA transfection, PS-1 cells were re-plated in their own conditioned medium in a 
96 well plate and proliferation was determined by BrdU assay.  Graph shows mean absorbance ±SEM 
(n=12 from 2 independent experiments). (C), PS-1 cells were treated +/- 10µg/ml rhSPARC and BrdU 
incorporation was measured for the last 24hrs of 72hr culture (n=18-36 from 3-6 independent 
experiments. (D) Representative western blot and table show vimentin expression in transfected PS-
1 cells (n=6 from 6 independent experiments).  (E) Vimentin expression in transfected PS-1 cells 
grown in complete medium on coverslips in a 6 well plate was also determined by quantitative 
microscopy using ImageJ software. Representative images of vimentin expression are shown in (E), 
where the scale bar represents 200µm (taken with 10X objective), and quantitative data is shown in 
(F), where the graph shows relative intensity of vimentin (n=9 from 3 independent experiments). Cell 
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density was also determined from these images, and mean cell density +/-SEM is shown in (G). 
Representative western blot in (H) shows TGF-β expression in PS-1 cells cultured for 3 consecutive 
days after re-plating following transfection with SPARC or control siRNA. Graph in (I) shows mean 
TGF-β expression relative to day 0 control. Data pooled from 3 independent experiments (n=3). All 
experiments performed in complete media (10% FBS). 
 
Figure 4: Purified SPARC mimics the effect of PS-1-derived SPARC. (A&B), rhSPARC and PS-1-derived 
SPARC were treated with PNGaseF to remove N-linked glycosylation and analysed by western blot.  
Representative blots are shown in (A), and in (B) the mean molecular weight of rhSPARC and PS-1 
SPARC pre- and post-deglycosylation from 5 independent experiments is shown, determined using 
Image Studio Lite V. 4.0 software. In (C), pancreatic cancer cells were treated with 10µg/ml rhSPARC 
in complete medium (10% FBS), n=18-30 from 3-5 independent experiments. 
 
Figure 5: Fibronectin controls proliferative SPARC function. (A) Pancreatic cancer cells were 
cultured in low serum (0.5% FBS) conditioned medium collected from control- or SPARC-siRNA 
transfected PS-1 cells (n=24-60 from 3-4 independent experiments). (B) AsPC-1 and Hpaf cells were 
cultured in conditioned medium (10% or 0.5% FBS) from PS-1 cells transfected with control- or 
SPARC-siRNA. A different SPARC siRNA was used for this experiment, targeting a distinct sequence 
from that used in earlier experiments (see methods for details; validation of knockdown is shown in 
Figure 1E). Graph shows relative absorbance ±SEM (n= 24 from 4 independent experiments). (C) 
AsPC-1 cells were cultured in medium containing 10% FBS, 0.25% BSA (0% FBS) and 0% FBS and 
treated +/- 10µg/ml rhSPARC (n=12 from 2 independent experiments). (D), AsPC-1 cells were 
cultured in low serum medium (0.5% FBS) and treated with 10µg/ml rhSPARC, 140ng/ml TGF-β or 
both rhSPARC & TGF-β (n=17-18 from 3 independent experiments). Statistical significance was 
determined by two-way ANOVA. (E), AsPC-1 cells were cultured in low serum medium (0.5% FBS), 
complete medium (10% FBS) or complete medium depleted of fibronectin (10% FBS - FN), and 
treated +/- 10µg/ml rhSPARC (n=18 from 3 independent experiments). (F&G) AsPC-1 cells were 
cultured in 0.5% FBS +/- 10µg/ml rhSPARC SPARC and +/- fibronectin at either 500 Pg/ml (F) or 1 
mg/ml (G). In (A-G), proliferation was measured by BrdU assay for the last 24hrs of a 72hr culture, 
and graphs show mean relative absorbance ±SEM.   
 
Figure 6: Fibronectin switches SPARC activity from promoting cell growth to induction of 
apoptosis. (A-C), Hpaf cells were treated +/- 10 µg/ml rhSPARC and cultured for 72hrs, in either low 
serum (A), or normal 10% serum (B), conditions, and as indicated in (C). Detection of caspase-3/7 
activity was quantified every 24hrs over a 72 hour period using an Incucyte Zoom live cell imaging 
system (Essen Bioscience).  Graphs in (A&B) shown mean fluorescent area +/- SEM, representing 
caspase-3/7 activity. (C) Representative images at 72hrs are shown (n=18 from 3 independent 
experiments). Similar results were seen with AsPC-1 cells (data not shown).  (D&E) AsPC-1 cells were 
cultured in 10% FBS medium depleted of fibronectin and treated +/- SPARC for 72 hours (n=3). (D) 
cell number was determined by haemocytometer counting. (E) Early stage apoptosis was measured 
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An9-rabbit	Alexafluor488		 Life	Technologies	 A-11001 1:200	
An9-goat	Alexafluor488		 Life	Technologies	 A-11055 1:200	
An9-goat	collagen	I	polyclonal		 Abcam	 ab19811	 1:100	
An9-mouse	GFAP	monoclonal	 Sigma-Aldrich	 G3893	 1:50	
		 An9-mouse	vimen9n	(V9)	monoclonal	 Dako	 MO725	 1:200	
Western	blot	(WB)	 An9-mouse	β-ac9n	monoclonal	 Abcam	 ab8224	 1:5,000	
An9-rabbit	collagen	I	polyclonal	 Abcam	 ab34710	 1:2,500	
An9-mouse	α-SMA	monoclonal	 Abcam	 ab7817	 1:300	
An9-rabbit	SPARC	(H-90)	polyclonal	 Santa	Cruz	Biotechnology	 sc-25574 1:1,000	
An9-rabbit	TGF-β	polyclonal	 Abcam	 ab66043	 1:5,000	






















Albumin	 	 Yes	 Yes	 S1	
Cathepsin	K	 Yes	 	 Yes	 S2	
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medium	 (0.5%	 FBS).	 Post	 transfection,	 PS-1	 cells	were	 re-plated	 into	 a	 96	well	 plate	 in	 their	 own	
conditioned	media	and	BrdU	incorporation	was	measured	for	the	last	24hrs	of	72hr	culture	(n=20-40	
from	 2-3	 independent	 experiments).	 (B)	 TGF-β	 expression	was	 determined	 by	western	 blot	 in	 re-
plated	 control-/SPARC-siRNA	 transfected	 PS-1	 cells	 in	 low	 serum	 medium	 (0.5%	 FBS).	 A	
representative	blot	from	two	independent	experiments	is	shown.		Numbers	under	the	blot	indicate	
TGF-β	 band	 intensity	 standardised	 to	 β-actin	 loading	 control.	 (C-D)	 Vimentin	 expression	 in	
transfected	PS-1	cells	cultured	in	low	serum	medium	(0.5%	FBS)	on	coverslips	in	a	6	well	plate	was	




density	 +/-SEM	 is	 shown.	 	 (F-H)	 Collagen	 staining	 of	 non-permeabilised	 control-	 and	 SPARC-siRNA	
treated	PS1	cells	was	 imaged	using	confocal	microscopy.	 	Representative	 images	are	shown	 in	 (F),	
with	quantification	of	staining	intensity	(G)	and	area	(H)	also	shown	(n=3,	with	3-4	images	quantified	
per	 slide).	 	 Secondary	 only	 control	 staining	 for	 both	 collagen	 and	 vimentin	 was	 blank.	 	 (I&J)	 Cell	
lysates	from	control-	and	SPARC-siRNA	treated	cells	were	analysed	by	western	blot	for	expression	of	
collagen	 I	 (I)	 and	α-SMA	 (J).	 	 ‘L’	 indicates	 size	marker/ladder.	 Quantification	 of	 band	 intensity	 	 is	
shown	under	each	blot,	standardised	to	β-actin	loading	control	and	relative	to	the	first	lane.	
	
Supplementary	 figure	 3:	 Fibronectin	 quantification.	 ELISA	 was	 used	 to	 measure	 fibronectin	
concentration	 (A)	 in	 FBS	 samples	 before	 and	 after	 fibronectin	 depletion	 using	 gelatin-sepharose	
depletion	(n=3),	and	(B)	in	media	from	PS-1	cells	following	treatment	with	either	control-	or	SPARC-
siRNA,	in	0.5%	and	10%	serum	as	indicated	(n=6	from	two	independent	experiments).	
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